Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
UBS
Accenture
Covington
Colorcon
McKesson
Julphar
Daiichi Sankyo

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,301,932

« Back to Dashboard

Which drugs does patent 9,301,932 protect, and when does it expire?

Patent 9,301,932 protects ORFADIN and is included in one NDA.

This patent has twenty patent family members in twenty countries.
Summary for Patent: 9,301,932
Title:Liquid pharmaceutical composition comprising nitisinone
Abstract: The invention concerns a liquid pharmaceutical formulation suitable for oral administration, comprising a suspension of an effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, e.g. in hereditary tyrosinaemia type I.
Inventor(s): Svensson; Lennart (Solna, SE), Siden; Hans (Sollentuna, SE)
Assignee: SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB (Stockholm, SE)
Application Number:14/129,090
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 9,301,932

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Swedish Orphan ORFADIN nitisinone SUSPENSION;ORAL 206356-001 Apr 22, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANIE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,301,932

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden1150585Jun 23, 2011
PCT Information
PCT FiledJune 20, 2012PCT Application Number:PCT/SE2012/050681
PCT Publication Date:December 27, 2012PCT Publication Number: WO2012/177214

International Family Members for US Patent 9,301,932

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012273515 ➤ Try a Free Trial
Brazil 112013033008 ➤ Try a Free Trial
Canada 2838039 ➤ Try a Free Trial
China 103747781 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
Express Scripts
Covington
Harvard Business School
McKesson
Baxter
Cipla
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.